ACTEMRA® 400 mg/20 mL is a biologic immunotherapy used to reduce inflammation and improve outcomes in patients with autoimmune inflammatory diseases. Each single-dose vial contains 20 mg/mL of tocilizumab, a monoclonal antibody that targets the interleukin-6 (IL-6) receptor — a major driver of chronic immune overactivity. By blocking IL-6 signaling, ACTEMRA® helps control symptoms such as joint pain, swelling, fatigue, and systemic inflammation while slowing disease progression.

This formulation is specifically designed for intravenous infusion in a clinical setting, allowing controlled dosing and continuous monitoring by healthcare professionals.

Key Benefits

• Helps reduce pain, swelling, stiffness, and fatigue

• Improves physical function and daily mobility

• Can slow structural joint and tissue damage

• Suitable for patients who have not responded well to other DMARDs or biologics

• Clinically proven for multiple autoimmune conditions

How It Works
ACTEMRA® inhibits IL-6 receptor activity, preventing the inflammatory signals that contribute to joint damage, systemic symptoms, and immune dysregulation in chronic inflammatory diseases. This targeted mechanism helps restore balance to the immune system.

Ideal Candidates

• Adults with rheumatoid arthritis who require biologic therapy

• Pediatric patients with polyarticular or systemic juvenile idiopathic arthritis (as indicated)

• Patients with cytokine release syndrome (CRS) related to cellular immunotherapies

• Individuals needing specialist-supervised IV biologic treatment

Administration

• Supplied as 400 mg/20 mL single-use vial

• Infusion performed by trained medical personnel under monitoring

• Weight-based dosing regimen determined by a specialist

• Regular clinical evaluation required for ongoing therapy

Possible Side Effects

• Headache, infusion-site reactions, or elevated liver enzymes

• Increased susceptibility to infections — screening and monitoring recommended

• Rare risks include hypersensitivity reactions and gastrointestinal complications

• Live vaccines should be avoided during treatment